Moreover, it is worth noting that a higher expression of KLK3 correlated with better clinical outcomes (HR = 0.423, 95% CI = 0.265–0.677, p = 0.0002, Figure 1, Table 1), and this finding was consistent with other research demonstrating that patients with positive lymph nodes, BCR, and metastatic disease, as well as those who died from PC, had significantly lower expression levels of KLK3 [9,40]. The gene discussed is KLK3; the disease is metastatic neoplasm.